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Purpose: To determine whether the effect of a single initial intravitreal injection of bevacizumab 
for neovascular age-related macular degeneration (AMD) persists for 8 weeks.
Methods: We reviewed the records of 25 consecutive patients with neovascular AMD treated 
with intravitreal bevacizumab. Patients were included (n = 15) if follow up data were available 
from 4 and 8 week visits after a single initial injection. Additionally, optical coherence 
tomography (OCT) images were graded qualitatively in a masked fashion by a single reader.
Results: Baseline mean visual acuity was 20/200, improving to 20/125 at 4 weeks (p = 0.0153) 
and 20/100 at 8 weeks (p = 0.0027). Mean central retinal thickness was 316 ± 107 μm at baseline 
and decreased to 223 ± 70 μm and 206 ± 45 μm at 4 and 8 weeks post-injection, respectively 
(p = 0.0003 and 0.0005). By masked OCT grading, macular ﬂ  uid was resolved in 10/15 (66.7%) 
and 11/15 (73.3%) eyes at 4 and 8 weeks, respectively, and 3/15 (20%) eyes had continued 
reduction in residual macular ﬂ  uid between 4 and 8 weeks.
Conclusions: A single initial bevacizumab injection has persistent clinical beneﬁ  t lasting 
8 weeks in most eyes with neovascular AMD. Results of prospective randomized studies are 
needed before changes in treatment regimens can be recommended.
Keywords: age-related macular degeneration, bevacizumab, choroidal neovascular membrane, 
optical coherence tomography
Introduction
Vascular endothelial growth factor (VEGF) is a mediator of many pathologic condi-
tions, including neovascular age-related macular degeneration (AMD) (Lopez et al 
1996; Kvanta et al 1996). Pegaptanib sodium (OSI/Eyetech, Melville, NY), an aptamer 
that targets the 165 amino-acid isoform of VEGF, was the ﬁ  rst anti-VEGF agent 
approved for the treatment of neovascular AMD. Intravitreal pegaptanib administered 
every six weeks was shown to slow the rate of vision loss compared with a sham-
injected control group after one year (Gragoudas et al 2004). More recently, intravitreal 
injections of the anti-VEGF reagents, ranibizumab (Lucentis; Genentech, Inc., South 
San Francisco, CA) and bevacizumab (Avastin; Genentech, Inc.) have been shown to 
result in improvement in mean visual acuity in treated eyes (Avery et al 2006; Heier 
et al 2006). Ranibizumab and bevacizumab were genetically engineered from the 
same murine monoclonal antibody against VEGF-A, the angiogenic protein consid-
ered to be the primary driver of choroidal neovascular membranes (Aiello et al 1995; 
Rakic et al 2003; Matsuoka et al 2004). Ranibizumab is a humanized antigen-binding 
fragment (Fab) against VEGF and was approved by the United States Food and Drug 
Administration (FDA) in June, 2006 based upon phase III MARINA and ANCHOR 
trials which conﬁ  rmed its safety and efﬁ  cacy (Brown et al 2006; Rosenfeld et al 
2006a). Bevacizumab is a full length, humanized monoclonal antibody against VEGF Clinical Ophthalmology 2008:2(4) 728
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and is FDA-approved for the treatment of metastatic colon 
cancer by intravenous use. The off-label use of intravenous 
bevacizumab for the treatment of neovascular AMD was 
initially reported by Michels and colleagues (Michels et al 
2005). Subsequently, uncontrolled, retrospective and pro-
spective case series have demonstrated short-term efﬁ  cacy 
of intravitreal bevacizumab in neovascular AMD (Rosenfeld 
et al 2005; Avery et al 2006; Bashshur et al 2006; Rich et al 
2006; Spaide et al 2006).
While growing evidence supports the use of off-label 
intravitreal bevacizumab in the treatment of exudative 
AMD, little is known about the optimal dosing paradigm for 
this antibody. Typically, clinicians have followed patients 
monthly after the initial dose of bevacizumab and re-injected 
for persistent cystic maculopathy and/or sub-retinal ﬂ  uid 
by clinical examination and optical coherence tomography 
(OCT) imaging (Avery et al 2006; Bashshur et al 2006; 
Rich et al 2006). There is little scientiﬁ  c evidence to sup-
port this strategy. Rather it evolved from the dosing regimen 
employed in the ranibizumab clinical trials (Heier et al 2006; 
Rosenfeld et al 2006b). In the ANCHOR and MARINA 
trials, patients randomized to the ranibizumab arm received 
monthly injections for the duration of the trial (Brown et al 
2006; Rosenfeld et al 2006a). However, the fact that bevaci-
zumab (149 kDa) and ranibizumab (48 kDa) have different 
molecular weights presumably alters their pharmacokinetic 
behavior when given intravitreally. Mordenti and colleagues 
(1999) showed in nonhuman primates that trastuzumab 
(Herceptin; Genentech, Inc), a full-length antibody similar 
to bevacizumab, has a vitreous half-life of 5.6 days while 
an antibody Fab similar to ranibizumab has a half-life of 3.2 
days. Given the increased half-life of the full sized antibody, 
it is reasonable to suspect that bevacizumab requires less 
frequent dosing than ranibizumab. We hypothesized that 
the effects of an initial bevacizumab injection would persist 
beyond the 4 week period when patients have typically 
been reexamined and reinjected for persistent exudation. 
We therefore tested whether the clinical effects of a single 
initial intravitreal bevacizumab injection persist for 8 weeks 
in eyes with neovascular AMD.
Methods
We retrospectively reviewed the medical records of consecu-
tive patients with neovascular AMD treated with intravit-
real bevacizumab by one of the authors (MWJ). Between 
November, 2005 and June, 2006, 25 patients received an 
initial injection of bevacizumab as part of their clinical care 
for active neovascular AMD. Disease activity was detected 
on biomicroscopic examination and conﬁ  rmed by ﬂ  uorescein 
angiography and OCT, with indocyanine angiography as 
needed to characterize retinal angiomatous proliferation 
(RAP) lesions. Approval to perform the retrospective review 
was obtained from our Institutional Review Board.
The standard clinical treatment regimen employed during 
the time period of this retrospective study was two induction 
injections given two months apart, followed by subsequent 
reinjection as needed for recurrent exudation. Following the 
initial injection, patients were not routinely retreated earlier 
than two months, even if cystoid macular edema, subretinal 
ﬂ  uid or subretinal pigment epithelial (RPE) ﬂ  uid persisted at 
one month. Patients (n = 15) were included in this analysis if 
complete follow up data, including Snellen visual acuity and 
OCT, were available from 4 and 8 week visits after the initial 
injection. No patient included in this study was re-injected 
with bevacizumab or received any other AMD intervention 
prior to their 8 week post-injection visit.
Patients were informed of the off-label use of intravit-
real bevacizumab (Avastin; Genentech, Inc.) and received 
a thorough discussion of all risks, potential beneﬁ  ts and 
alternative treatment options. Aliquots (0.12 ml) of com-
mercially available bevacizumab (Avastin) were placed in a 
tuberculin syringe by a compounding pharmacy using aseptic 
technique. Aliquots were stored at 4 °C until used (within 
14 days of preparation). Following topical antibiotic drops 
and anesthesia with proparacaine and 4% lidocaine, the eye 
was cleaned with 10% povidone-iodine and draped in a sterile 
fashion. A lid speculum was placed in the eye. Bevacizumab 
(1.25 mg in 0.05 cc) was injected through a 30 gauge needle 
introduced into the vitreous cavity 3.5–4.0 mm from the 
limbus. Topical antibiotic was applied and the intraocular 
pressure was monitored.
Patients returned to the clinic at 4 and 8 weeks following 
injection with bevacizumab. At these visits, Snellen visual 
acuity was measured and fundus biomicroscopy and OCT 
imaging were performed. OCT imaging included 6 diagonal, 
fast, low-density 6-mm scans performed at 30 degree inter-
vals. The average thickness of the central 1-mm subﬁ  eld was 
determined from the fast macular thickness maps calculated 
from the 6 low-resolution diagonal scans. No attempt was 
made retrospectively to adjust for improper retinal boundar-
ies determined by automated OCT analysis. In addition, two 
high-density, high-resolution scans in a cross-hair conﬁ  gu-
ration were obtained and used to qualitatively evaluate the 
degree of macular exudation at the baseline, 4 and 8 week 
visits. As part of this retrospective study, OCT images were 
graded by a single reader masked to the identity of the patient, Clinical Ophthalmology 2008:2(4) 729
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visit date and mean central retinal thickness measurements. 
Macular ﬂ  uid (deﬁ  ned as cystoid edema and/or subretinal 
ﬂ  uid) and sub-RPE ﬂ  uid were analyzed separately for each 
visit. The baseline OCT was identiﬁ  ed and compared to the 
masked 4 and 8 week post-injection OCTs. Each set was 
graded as to whether the ﬂ  uid components were resolved, 
improved (but not resolved), unchanged or worsened.
Statistical comparisons of mean central thickness mea-
surements and logMAR visual acuities were performed 
using two-tailed paired t-tests (SAS, Version 9.1, Cary, 
NC). A p value of 0.05 was considered to be statistically 
signiﬁ  cant.
Results
Fifteen eyes of ﬁ  fteen patients met the inclusion criteria 
for this retrospective study; none of these patients were 
excluded from analysis. Mean patient age was 79.7 years 
(range, 63–89). There were seven men (46.7%) and eight 
women (53.3%). Seven of ﬁ  fteen (46.7%) eyes had received 
previous treatment for exudative AMD including laser pho-
tocoagulation (3), photodynamic therapy with verteporﬁ  n (3) 
and pegaptanib (2). Choroidal neovascular membranes were 
characterized as occult-only in 6/15 (40%) eyes, predomi-
nantly classic in 2/15 (13.3%) eyes and minimally classic in 
2/15 (13.3%) eyes. Five of ﬁ  fteen (33.3%) eyes had retinal 
angiomatous proliferation lesions.
Table 1 shows mean visual acuity and central retinal 
thickness measurements. Compared with baseline values of 
20/200 (logMAR 0.98 ± 0.44), mean visual acuity improved 
by 4 weeks to 20/125 (logMAR 0.76 ± 0.35, p = 0.0153). 
Without additional bevacizumab injections, the visual 
improvement was maintained through 8 weeks, with a mean 
visual acuity of 20/100 (logMAR 0.70 ± 0.34, p = 0.0027). 
At the 4 week follow-up, three eyes (20%) had an improve-
ment in visual acuity of at least 3 lines and at week 8, ﬁ  ve 
eyes (33.3%) had at least a 3-line improvement. Similar 
results were found when comparing the mean central retinal 
thickness. Mean central retinal thickness was 316 ± 107 μm 
at baseline and decreased to 223 ± 70 μm (p = 0.0003) and 
206 ± 45 μm (p = 0.0005) at 4 and 8 weeks post-injection, 
respectively (Table 1).
Figures 1A and 1B show the distribution of individual 
patients with respect to visual acuity at baseline and at 4 
weeks or 8 weeks, respectively. Following a single bevaci-
zumab injection, stable (within 1 Snellen line) or improved 
vision was seen in all 15 (100%) eyes at 4 and 8 weeks. 
Without additional injections, the visual acuity remained 
stable or improved further between 4 and 8 weeks in all eyes 
(Figure 1C).
Figures 2A and 2B plot the distribution of individual 
patients with respect to central retinal thickness measure-
ments at baseline and at week 4 or week 8, respectively. 
Compared with baseline, stable (within 50 μm) or decreased 
central thickness was seen in all 15 (100%) eyes by 4 weeks 
(Figure 2A). These results persisted at 8 weeks (Figure 2B). 
Between 4 and 8 weeks, central retinal thickness measure-
ments were stable (within 50 μm) in 11/15 (73.3%) eyes, 
improved in 3 (20%) eyes, and worsened in 1 (6.7%) eye 
(Figure 2C). In the lone eye that showed worsening between 
4 and 8 weeks, the visual acuity remained stable during this 
period.
Results of the masked evaluation of OCT images are 
presented in Table 2. Following a single initial intravitreal 
bevacizumab injection, macular ﬂ  uid (cystoid edema and/or 
subretinal ﬂ  uid) was resolved in 10/15 (66.7%) patients at 4 
weeks and 11/15 (73.3%) patients at 8 weeks. Masked com-
parison of the 4 and 8 week OCT images showed that 3/15 
(20%) patients had continued reduction in residual macular 
ﬂ  uid between these time points (Table 2, Figure 3). The macular 
ﬂ  uid was graded as worse at 8 weeks compared with 4 weeks in 
only 1 (6.7%) patient, and was unchanged in the remaining 11 
(73.3%) patients (Figure 4). Six of the 15 patients in our study 
had a serous pigment epithelial detachment (PED) component 
at the pre-injection visit. The response of the sub-RPE ﬂ  uid in 
these eyes was similar to that of the cystoid macular edema and 
subretinal ﬂ  uid. The serous RPE detachment had resolved in 
4/6 (67.7%) patients at both the 4 and 8 week post-injection 
visits (Table 2). Between 4 and 8 weeks, 1/6 (16.7%) patients 
Table 1 Mean visual acuity and central retinal thickness following a single bevacizumab injection (n = 15)
  Baseline  Week 4  Week 8
Mean Va ± SD (logMAR)  0.98 ± 0.44  0.76 ± 0.35 (p = 0.0153)  0.70 ± 0.34 (p = 0.0027)
Mean Va (Snellen)  20/200  20/125  20/100
3 line improvement in Va  NA  3/15 (20%)  5/15 (33.3%)
Mean central retinal thickness ± SD (μm) 316  ± 107  223 ± 70 (p = 0.0003)  206 ± 45 (p = 0.0005)
Abbreviations: Va, visual acuity; logMAR, logarithm of minimum angle of resolution; NA, not applicable; SD, standard deviation.Clinical Ophthalmology 2008:2(4) 730
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had further resolution of residual sub-RPE ﬂ  uid, while the 
remaining patient demonstrated no change in residual sub-RPE 
ﬂ  uid. No eyes showed an increase in sub-RPE ﬂ  uid during this 
time interval.
Discussion
Intravitreal bevacizumab has been shown to be effective in 
the management of exudative AMD (Rosenfeld et al 2005; 
Avery et al 2006; Bashshur et al 2006; Rich et al 2006; 
Spaide et al 2006). While ranibizumab has become the gold 
standard for neovascular AMD since its approval by the 
FDA, off-label use of bevacizumab remains widespread, 
owing in part to cost considerations. Cost aside, some 
patients and clinicians might be inclined to use bevacizumab 
if certain therapeutic properties, such as duration of action, 
are shown in future clinical trials to be advantageous 
compared with ranibizumab. Because bevacizumab is 
approximately three times larger than ranibizumab, and 
because previous studies have demonstrated a 75% increase 
in the intravitreal half-life of a full-length antibody compared 
to an antibody fragment, we hypothesized that the effects 
of an initial dose of intravitreal bevacizumab would persist 
for 8 weeks in most eyes.
The anatomical and visual response to a single injection 
of intravitreal bevacizumab in our patients appear to support 
this hypothesis. The mean central retinal thickness decreased 
from 316 μm at baseline to 223 μm at 4 weeks post-injection. 
Without further bevacizumab injections, there was a trend 
toward continued improvement in mean central retinal thick-
ness to 206 μm between 4 and 8 weeks. Similarly, mean 
Snellen visual acuity improved from 20/200 at baseline to 
20/125 at 4 weeks and 20/100 at 8 weeks.
Importantly, masked qualitative evaluation of high-
resolution OCT scans conﬁ  rmed the anatomical response 
suggested by automated central retinal thickness measure-
ments. We performed the qualitative analysis because of the 
inherent limitations of automated quantitative OCT thickness 
measurement in the complex macular anatomy of neovascular 
AMD. As emphasized by previous authors (Sadde et al 2006), 
retinal thickness measurement errors occur frequently in 
AMD with current Stratus OCT analysis algorithms, in part 
because of poor patient ﬁ  xation, difﬁ  culty in determining 
anterior and posterior retinal boundaries, and the inability 
to take into account the presence of sub-RPE ﬂ  uid. Because 
of these limitations, qualitative evaluation of OCT scans is 
a more accurate method of assessing the macular anatomic 
response to anti-VEGF therapy.
In our study, masked qualitative analysis of OCT scans 
showed that the macular ﬂ  uid (macular edema and/or subreti-
nal ﬂ  uid) status was stable or showed continued improvement 
in 14/15 (93%) of patients between 4 and 8 weeks following a 
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Figure 2 Distribution of central 1-mm retinal thickness (CRT) at baseline, 4 and 8 
weeks following a single bevacizumab injection. Decreased central retinal thickness is 
represented by points above the line. A) Baseline versus 4 weeks. B) Baseline versus 
8 weeks. C) 4 weeks versus 8 weeks.
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Figure 1 Distribution of visual acuity (logMAR) in 15 eyes between baseline, 4 and 
8 weeks following a single bevacizumab injection. Interval improvement in vision is 
represented by points above the line. A) Baseline versus 4 weeks. B) Baseline versus 
8 weeks. C) 4 weeks versus 8 weeks.Clinical Ophthalmology 2008:2(4) 731
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single bevacizumab injection. The remaining patient showed 
a mild increase in macular ﬂ  uid during this time period. 
Similarly, by masked grading, sub-RPE ﬂ  uid status between 
4 and 8 weeks continued to improve or was stable in 6/6 eyes 
(100%) with a serous RPE detachment component at baseline. 
Using similar qualitative OCT analysis, Costa and colleagues 
(2006) found in a phase I dose-escalation study that macular 
architecture was stable or improved from baseline in 91.1% 
of eyes at 6 weeks and 83.7% of eyes at 12 weeks following 
a single initial bevacizumab injection for exudative AMD. 
Within each dose group, more eyes demonstrated favorable 
macular remodeling on angiographic and OCT evaluations 
at 6 weeks compared with 12 weeks, suggesting a decline in 
biologic activity during this time period.
These data suggest that bevacizumab can be initially dosed 
in most eyes at intervals of 6 to 8 weeks. The observation that a 
subset of eyes shows continued improvement in macular and/or 
sub-RPE ﬂ  uid between 4 and 8 weeks after a single injection 
and that ﬂ  uid reaccumulation rarely occurs during this period 
suggests that a pharmacologic effect initially persists in the eye 
for approximately two months. Reinjection of bevacizumab 
for persistent macular or sub-RPE ﬂ  uid at 4 weeks is probably 
unnecessary in most cases, since continued resolution of ﬂ  uid 
over the subsequent month may occur without reinjection. 
Table 2 Masked grading of OCT images at baseline, 4, and 8 weeks
 Macular  ﬂ  uid (15 eyes)  Sub-RPE ﬂ  uid (6 eyes)
  Baseline to   Baseline to   4 weeks to   Baseline to   Baseline to   4 weeks to 
  4 weeks n (%)  8 weeks n (%)  8 weeks n (%)  4 weeks n (%)  8 weeks n (%)  8 weeks n (%)
Resolved  10 (66.7%)  11 (73.3%)  NA  4 (66.7%)  4 (66.7%)  NA
Improved  3 (20%)  3 (20%)  3 (20%)  1 (16.7%)  2 (33.3%)  1 (16.7%)
Unchanged  2 (13.3%)  1 (6.7%)  11 (73.3%)  1 (16.7%)  0  5 (83.3%)
Worsened  0 0 1  (6.7%)  0 0 0
Abbreviations: OCT, optical coherence tomography; RPE, retinal pigment epithelium; NA, not applicable.
Figure 3 Representative optical coherence tomography (OCT) images of an eye with retinal angiomatous proliferation that had improvement in macular and subretinal 
pigment epithelial ﬂ  uid between 4 and 8 weeks following a single intravitreal injection of bevacizumab. A) Baseline OCT images through central macula. B) OCT images at 4 
weeks. C) OCT images at 8 weeks.Clinical Ophthalmology 2008:2(4) 732
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Similarly, a macula that is dry at 4 weeks is very likely to 
remain dry at 8 weeks without additional treatment.
Accumulating clinical experience with as-needed or vari-
able dosing regimens suggests that signiﬁ  cant interindividual 
variation with respect to retreatment interval is a common 
feature of anti-VEGF therapy for neovascular AMD (Avery 
et al 2006; Rosenfeld et al 2006c; Fung et al 2007). However, 
extended follow-up of a cohort of patients treated with beva-
cizumab reinjection as needed for recurrent macular exuda-
tion found an average reinjection interval of 2 months during 
the ﬁ  rst 6 months of treatment (Avery RL, Presented at The 
Combined Meeting of the Club Jules Gonin and The Retina 
Society, October, 2006; Cape Town, South Africa). Simi-
larly, Aisenbrey and colleagues (2007) reported a median 
reinjection interval of 8 weeks in patients with exudative 
AMD who received bevacizumab reinjection as needed for 
worsening vision or exudation. In agreement with our data, 
these results suggest that most patients receiving intravitreal 
bevacizumab for exudative AMD can be followed initially at 
6 to 8 week intervals, with subsequent titration of reinjection 
frequency depending on the individual clinical response.
Obviously, a dosing schedule that requires fewer injec-
tions provides signiﬁ  cant advantages in terms of ocular 
safety, cost, and patient convenience and discomfort. Less 
frequent intravitreal dosing of a given drug also reduces sys-
temic exposure to the drug and reduces the risk of systemic 
adverse events. Although encouraging, the results of this 
study must be interpreted in the context of its retrospec-
tive design, small number of patients, lack of standardized 
visual acuity testing, and short follow-up. Further research is 
necessary to provide further clariﬁ  cation of the ideal dosing 
strategy for bevacizumab and other anti-VEGF agents.
A planned prospective, randomized, multi-center clinical 
trial sponsored by the National Eye Institute (Comparison 
of Age-Related Macular Degeneration Treatments Trials: 
Lucentis-Avastin Trial, www.clinicaltrials.gov) will provide 
critical data comparing the efﬁ  cacy and safety of ranibizumab 
with bevacizumab for neovascular AMD. Importantly, this 
Horizontal Vertical
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Figure 4 Representative optical coherence tomography (OCT) images of an eye with retinal angiomatous proliferation that had resolution of macular and subretinal pigment 
epithelial ﬂ  uid at 4 weeks and maintained a dry macula at 8 weeks after a single intravitreal bevacizumab injection. A) Baseline OCT images through central macula. B) OCT 
images at 4 weeks. C) OCT images at 8 weeks.Clinical Ophthalmology 2008:2(4) 733
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trial will also compare ﬁ  xed versus variable dosing schedules 
for each drug. Ultimately, this data will be needed to deter-
mine with certainty whether the beneﬁ  ts of less frequent 
dosing with bevacizumab can be realized without sacriﬁ  cing 
the efﬁ  cacy or safety proven with monthly ranibizumab.
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